Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus

Neurology

Volumn 77, Issue 21, 2011, Pages 1866-1872

  Mishra, N K ^a   Ahmed, N ^b   Davalos, A ^c   Iversen, H K ^d   Melo, T ^e   Soinne, L ^f   Wahlgren, N ^b   Lees, K R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF LISBON   (Portugal)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ANAMNESIS; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; STROKE PATIENT; SURVIVAL;

EID: 82955243840     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318238ee42     Document Type: Conference Paper

References (24)

1. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333: 1581-1587.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
4. Summary information on a referral opinion following an arbitration pursuant to article 29 of directive 2001/83/EC for Actilyse (dated 21 November, 2002; CPMP/3346/02-EN), prepared by the Committee for Proprietary Medicinal Products (CPMP) for the European Agency for the Evaluation of Medicinal Products. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/Actilyse-29/WC500010327.pdf. Accessed October 2, 2011.
5. Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: Controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010;341:c6046.
6. Ali M, Bath PM, Curram J, et al. The Virtual International Stroke Trials Archive. Stroke 2007;38:1905-1910. (Pubitemid 46847267)
7. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007;369: 275-282. (Pubitemid 46138121)
8. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008;372:1303-1309.
9. Kulkens S, Hacke W. Thrombolysis with alteplase for acute ischemic stroke: Review of SITS-MOST and other phase IV studies. Expert Rev Neurother 2007;7:783-788. (Pubitemid 47037718)
10. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of age on outcome from thrombolysis in acute stroke: A controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2840-2848.
11. Mishra NK, Davis S, Kaste M, Lees K. Comparison of outcomes following thrombolytic therapy amongst patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010; 33:2531-2537.
12. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600. (Pubitemid 43209106)
13. Lees KR, Davalos A, Davis SM, et al. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 2006;37:2970-2978. (Pubitemid 44900818)
14. Brown DL, Coffey CS. Stroke trials: A shift to shift analysis? Neurology 2009;72:1292-1293.
15. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009;72:1310-1315.
16. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007;38:3205-3212. (Pubitemid 350175738)
17. Gray LJ, Bath PM, Collier T. Should stroke trials adjust functional outcome for baseline prognostic factors? Stroke 2009;40:888-894.
18. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 2007;38:414-416. (Pubitemid 46184318)
19. Mann J. tPA for acute stroke: Balancing baseline imbalances. CMAJ 2002;166:1651-1652; author reply 1652-1653.
20. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009;8:50-61.
21. Senn S, Julious S. Measurement in clinical trials: A neglected issue for statisticians? Stat Med 2009;28:3189-3209.
22. Bluhmki E, Windeler J, Hacke W. [Neurological scales as endpoints in stroke studies: Aspects of statistical evaluation.] Nervenarzt 2000;71:797-801.
23. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055-3062. (Pubitemid 350035704)
24. Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009;8:1095-1102.